SEC Form 4	
------------	--

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

1. Name and Address of Reporting Person* BOGER JOSHUA S	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)         X       Director         10%       Owner         X       Officer (give title below)       Other (specify below)				
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET	3. Date of Earliest Transaction (Month/Day/Year) 12/07/2007	President & CEO				
I 30 WAVERLY STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	12/07/2007		М		17,686	A	\$13.67	1,113,528	D	
Common Stock	12/07/2007		S <sup>(1)(2)</sup>		600	D	\$25.95	1,112,928	D	
Common Stock	12/07/2007		S <sup>(1)(3)</sup>		1,900	D	\$25.85	1,111,028	D	
Common Stock	12/07/2007		S <sup>(1)(4)</sup>		3,400	D	\$25.74	1,107,628	D	
Common Stock	12/07/2007		S <sup>(1)(5)</sup>		6,600	D	\$25.64	1,101,028	D	
Common Stock	12/07/2007		S <sup>(1)(6)</sup>		2,200	D	\$25.55	1,098,828	D	
Common Stock	12/07/2007		S <sup>(1)(7)</sup>		2,186	D	\$25.45	1,096,642	D	
Common Stock	12/07/2007		S <sup>(1)(8)</sup>		800	D	\$25.34	1,095,842	D	
Common Stock								12,445	Ι	401(k)
Common Stock								207,500	I	Shares in trust <sup>(10)</sup>

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$13.67	12/07/2007		М			17,686	(9)	12/11/2007	Common Stock	17,686	\$0	0	D	

### Explanation of Responses:

1. Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.

2. Aggregate sales made at prices between \$25.91 and \$26.02.

3. Aggregate sales made at prices between \$25.81 and \$25.89.

4. Aggregate sales made at prices between \$25.70 and \$25.79.

5. Aggregate sales made at prices between \$25.60 and \$25.69.

6. Aggregate sales made at prices between \$25.50 and \$25.59.

7. Aggregate sales made at prices between \$25.40 and \$25.49.

8. Aggregate sales made at prices between \$25.25 and \$25.39.

9. Fully vested.

10. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

#### **Remarks:**

Valerie L. Andrews, Attorney-In-Fact \*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.